Datroway (datopotamab deruxtecan) has become the first oncology drug to significantly improve overall survival compared to chemotherapy in an aggressive form of invasive breast cancer.
A topical formulation of an existing neurocosmetic drug available in the EU could offer a “targeted and safer alternative” for chemotherapy-induced peripheral neuropathy (CIPN), according to researchers in Spain
Merck & Co has expanded its clinical development programme for tulisokibart (MK-7240), adding phase IIb trials for a trio of immune-mediated inflammatory diseases.
Today, the U.S. Food and Drug Administration (FDA) approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF), a rare, serious, and progressive disease with no cure and limited treatments. This is the first new therapy approved in more than 10 years for IPF.
On October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab …
The U.S. Food and Drug Administration (FDA) approved Palsonify (paltusotine) tablets to treat adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.
